 Mark Boguniewicz
Concepts (517)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 151 | 2024 | 307 | 22.250 |
Why?
| | Eczema | 14 | 2023 | 81 | 3.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 17 | 2023 | 660 | 2.390 |
Why?
| | Skin | 32 | 2024 | 653 | 1.990 |
Why?
| | Severity of Illness Index | 43 | 2023 | 2537 | 1.880 |
Why?
| | Tacrolimus | 20 | 2023 | 134 | 1.820 |
Why?
| | Pruritus | 15 | 2023 | 59 | 1.500 |
Why?
| | Dermatologic Agents | 13 | 2023 | 57 | 1.470 |
Why?
| | Antibodies, Monoclonal | 7 | 2023 | 1257 | 1.450 |
Why?
| | Quality of Life | 27 | 2023 | 2343 | 1.340 |
Why?
| | Immunosuppressive Agents | 14 | 2023 | 641 | 1.220 |
Why?
| | Staphylococcus aureus | 11 | 2023 | 385 | 1.150 |
Why?
| | Staphylococcal Skin Infections | 6 | 2018 | 29 | 1.140 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2024 | 39 | 1.100 |
Why?
| | Biological Products | 2 | 2020 | 166 | 1.100 |
Why?
| | Keratinocytes | 11 | 2024 | 215 | 1.090 |
Why?
| | Asthma | 15 | 2023 | 2021 | 1.030 |
Why?
| | Calcineurin Inhibitors | 14 | 2010 | 58 | 0.960 |
Why?
| | Kaposi Varicelliform Eruption | 12 | 2013 | 22 | 0.930 |
Why?
| | Humans | 170 | 2024 | 114045 | 0.870 |
Why?
| | Practice Guidelines as Topic | 9 | 2018 | 1381 | 0.850 |
Why?
| | Boron Compounds | 3 | 2018 | 17 | 0.760 |
Why?
| | Immunoglobulin E | 18 | 2023 | 314 | 0.750 |
Why?
| | Urticaria | 3 | 2008 | 36 | 0.730 |
Why?
| | Emollients | 4 | 2018 | 11 | 0.730 |
Why?
| | Double-Blind Method | 23 | 2023 | 1656 | 0.730 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2020 | 7 | 0.720 |
Why?
| | Hypersensitivity | 3 | 2023 | 252 | 0.710 |
Why?
| | Intermediate Filament Proteins | 7 | 2018 | 65 | 0.690 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2018 | 172 | 0.680 |
Why?
| | Adrenal Cortex Hormones | 10 | 2023 | 493 | 0.670 |
Why?
| | Dermatology | 3 | 2017 | 86 | 0.650 |
Why?
| | Bandages | 3 | 2016 | 30 | 0.650 |
Why?
| | Cytokines | 16 | 2023 | 1824 | 0.640 |
Why?
| | Administration, Topical | 15 | 2020 | 137 | 0.640 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 219 | 0.640 |
Why?
| | Allergy and Immunology | 2 | 2017 | 51 | 0.630 |
Why?
| | Expert Testimony | 1 | 2019 | 36 | 0.620 |
Why?
| | Anti-Inflammatory Agents | 11 | 2020 | 445 | 0.620 |
Why?
| | Skin Care | 4 | 2008 | 18 | 0.610 |
Why?
| | Interferon-gamma | 11 | 2013 | 719 | 0.600 |
Why?
| | Adult | 71 | 2023 | 30375 | 0.600 |
Why?
| | Treatment Outcome | 29 | 2023 | 9049 | 0.590 |
Why?
| | Biological Therapy | 1 | 2017 | 26 | 0.570 |
Why?
| | Interleukin-13 | 10 | 2023 | 121 | 0.560 |
Why?
| | Occlusive Dressings | 1 | 2016 | 5 | 0.550 |
Why?
| | Antimicrobial Cationic Peptides | 5 | 2010 | 75 | 0.540 |
Why?
| | Interleukin-4 | 9 | 2023 | 204 | 0.510 |
Why?
| | Herpes Simplex | 3 | 2013 | 87 | 0.510 |
Why?
| | Advisory Committees | 1 | 2017 | 207 | 0.510 |
Why?
| | Psoriasis | 10 | 2023 | 80 | 0.500 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 348 | 0.480 |
Why?
| | Cost of Illness | 9 | 2018 | 254 | 0.480 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 115 | 0.470 |
Why?
| | Epidermis | 3 | 2017 | 148 | 0.470 |
Why?
| | Autoimmune Diseases | 4 | 2018 | 381 | 0.450 |
Why?
| | Conjunctivitis | 3 | 2023 | 17 | 0.450 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 3 | 2018 | 6 | 0.440 |
Why?
| | Simplexvirus | 3 | 2011 | 80 | 0.440 |
Why?
| | Glycyrrhetinic Acid | 3 | 2008 | 7 | 0.440 |
Why?
| | Th2 Cells | 6 | 2017 | 154 | 0.430 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 347 | 0.430 |
Why?
| | Anti-Allergic Agents | 3 | 2014 | 41 | 0.420 |
Why?
| | Child | 40 | 2023 | 18401 | 0.410 |
Why?
| | Hypersensitivity, Immediate | 3 | 2019 | 46 | 0.410 |
Why?
| | Calcineurin | 5 | 2006 | 89 | 0.410 |
Why?
| | Desensitization, Immunologic | 4 | 2022 | 116 | 0.410 |
Why?
| | beta-Defensins | 7 | 2010 | 18 | 0.400 |
Why?
| | Child, Preschool | 30 | 2018 | 9114 | 0.400 |
Why?
| | Immunity, Innate | 6 | 2011 | 720 | 0.380 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 296 | 0.370 |
Why?
| | Allergens | 7 | 2023 | 410 | 0.360 |
Why?
| | Adolescent | 33 | 2023 | 17800 | 0.350 |
Why?
| | Drug Approval | 3 | 2020 | 78 | 0.350 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 926 | 0.350 |
Why?
| | Food Hypersensitivity | 5 | 2018 | 251 | 0.350 |
Why?
| | Ointments | 10 | 2016 | 23 | 0.340 |
Why?
| | Adaptive Immunity | 1 | 2011 | 154 | 0.340 |
Why?
| | Plant Extracts | 3 | 2008 | 154 | 0.340 |
Why?
| | Disease Progression | 6 | 2019 | 2371 | 0.340 |
Why?
| | Complementary Therapies | 1 | 2010 | 74 | 0.330 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 192 | 0.330 |
Why?
| | Staphylococcal Infections | 4 | 2023 | 340 | 0.330 |
Why?
| | Dietary Fats | 2 | 2008 | 287 | 0.320 |
Why?
| | Prevalence | 12 | 2019 | 2247 | 0.320 |
Why?
| | Off-Label Use | 2 | 2020 | 51 | 0.310 |
Why?
| | Drug Hypersensitivity | 3 | 1995 | 83 | 0.310 |
Why?
| | Inflammation | 4 | 2018 | 2464 | 0.310 |
Why?
| | Receptors, IgE | 1 | 2008 | 40 | 0.310 |
Why?
| | Male | 51 | 2023 | 55396 | 0.300 |
Why?
| | Population Groups | 2 | 2018 | 55 | 0.300 |
Why?
| | Administration, Cutaneous | 8 | 2016 | 117 | 0.300 |
Why?
| | Chronic Disease | 12 | 2019 | 1577 | 0.300 |
Why?
| | Self Report | 7 | 2019 | 695 | 0.300 |
Why?
| | Disease Management | 5 | 2020 | 556 | 0.290 |
Why?
| | United States | 19 | 2023 | 12137 | 0.290 |
Why?
| | Cross-Sectional Studies | 14 | 2021 | 4402 | 0.270 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 1471 | 0.270 |
Why?
| | Female | 49 | 2023 | 59324 | 0.260 |
Why?
| | Dermatitis, Allergic Contact | 2 | 2016 | 63 | 0.250 |
Why?
| | Infant | 22 | 2022 | 7943 | 0.240 |
Why?
| | Vaccinia virus | 4 | 2011 | 27 | 0.240 |
Why?
| | Patch Tests | 3 | 2016 | 51 | 0.240 |
Why?
| | Phototherapy | 3 | 2018 | 24 | 0.240 |
Why?
| | Omalizumab | 2 | 2020 | 45 | 0.240 |
Why?
| | Steroids | 3 | 2017 | 143 | 0.240 |
Why?
| | Diagnosis, Differential | 7 | 2008 | 1331 | 0.230 |
Why?
| | Exanthema | 1 | 2005 | 74 | 0.230 |
Why?
| | Anxiety | 3 | 2019 | 843 | 0.230 |
Why?
| | Janus Kinase Inhibitors | 1 | 2023 | 10 | 0.220 |
Why?
| | Middle Aged | 34 | 2019 | 26605 | 0.220 |
Why?
| | Ectropion | 1 | 2023 | 1 | 0.220 |
Why?
| | Janus Kinases | 1 | 2023 | 12 | 0.220 |
Why?
| | Blepharitis | 1 | 2023 | 3 | 0.220 |
Why?
| | Pain | 2 | 2019 | 701 | 0.210 |
Why?
| | Down-Regulation | 7 | 2017 | 594 | 0.210 |
Why?
| | Sublingual Immunotherapy | 1 | 2022 | 7 | 0.210 |
Why?
| | Receptors, Interleukin | 3 | 2020 | 39 | 0.200 |
Why?
| | Depression | 3 | 2019 | 1133 | 0.200 |
Why?
| | Tight Junctions | 3 | 2011 | 68 | 0.200 |
Why?
| | Sickness Impact Profile | 2 | 2019 | 50 | 0.200 |
Why?
| | Recurrence | 4 | 2019 | 925 | 0.200 |
Why?
| | Drug Industry | 2 | 2018 | 103 | 0.190 |
Why?
| | STAT6 Transcription Factor | 3 | 2011 | 22 | 0.190 |
Why?
| | Patient Education as Topic | 5 | 2015 | 666 | 0.180 |
Why?
| | Membrane Proteins | 4 | 2011 | 1016 | 0.180 |
Why?
| | Autoantibodies | 1 | 2008 | 1347 | 0.180 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 119 | 0.180 |
Why?
| | Consensus | 3 | 2017 | 532 | 0.180 |
Why?
| | Bacterial Toxins | 3 | 2012 | 103 | 0.170 |
Why?
| | Biomarkers | 6 | 2023 | 3397 | 0.170 |
Why?
| | Animals | 16 | 2023 | 31565 | 0.170 |
Why?
| | Injections, Subcutaneous | 4 | 2023 | 134 | 0.170 |
Why?
| | Pyrimidines | 1 | 2022 | 374 | 0.160 |
Why?
| | Skin Diseases, Infectious | 3 | 2008 | 15 | 0.160 |
Why?
| | Sulfonamides | 1 | 2022 | 444 | 0.160 |
Why?
| | Surveys and Questionnaires | 5 | 2019 | 4595 | 0.160 |
Why?
| | Patient Health Questionnaire | 1 | 2018 | 21 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2023 | 1204 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 82 | 0.150 |
Why?
| | Injections | 1 | 2019 | 160 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 6 | 2011 | 2090 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 4 | 2022 | 251 | 0.150 |
Why?
| | T-Lymphocytes | 6 | 2006 | 1735 | 0.150 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 232 | 0.150 |
Why?
| | Immunologic Factors | 2 | 2005 | 217 | 0.150 |
Why?
| | Guidelines as Topic | 2 | 2018 | 241 | 0.140 |
Why?
| | Gene Expression Regulation | 6 | 2011 | 2322 | 0.140 |
Why?
| | Skin Diseases | 1 | 2019 | 121 | 0.140 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1175 | 0.140 |
Why?
| | Skin Diseases, Viral | 2 | 2018 | 4 | 0.140 |
Why?
| | Personal Satisfaction | 1 | 2018 | 181 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 662 | 0.130 |
Why?
| | Gloves, Surgical | 1 | 1996 | 3 | 0.130 |
Why?
| | Gloves, Protective | 1 | 1996 | 2 | 0.130 |
Why?
| | Latex | 1 | 1996 | 9 | 0.130 |
Why?
| | Rubber | 1 | 1996 | 6 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 2 | 2019 | 675 | 0.130 |
Why?
| | Cells, Cultured | 13 | 2011 | 3861 | 0.130 |
Why?
| | Bronchial Hyperreactivity | 1 | 1996 | 94 | 0.130 |
Why?
| | Dermatitis, Occupational | 1 | 1996 | 13 | 0.130 |
Why?
| | Primary Health Care | 2 | 2016 | 1502 | 0.130 |
Why?
| | Histamine H1 Antagonists | 2 | 2006 | 28 | 0.130 |
Why?
| | Chemokines, CC | 3 | 2006 | 28 | 0.130 |
Why?
| | Receptors, Cytokine | 2 | 2010 | 33 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 268 | 0.120 |
Why?
| | Milk Proteins | 1 | 2015 | 36 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2019 | 479 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.120 |
Why?
| | Milk Hypersensitivity | 1 | 2015 | 21 | 0.120 |
Why?
| | Gene Expression Profiling | 4 | 2011 | 1518 | 0.120 |
Why?
| | Patient-Centered Care | 2 | 2018 | 470 | 0.120 |
Why?
| | Hydrotherapy | 1 | 2014 | 8 | 0.120 |
Why?
| | Patient Care Planning | 1 | 2015 | 138 | 0.120 |
Why?
| | Risk Factors | 8 | 2015 | 8614 | 0.120 |
Why?
| | Infant Formula | 1 | 2015 | 74 | 0.120 |
Why?
| | Algorithms | 3 | 2018 | 1469 | 0.120 |
Why?
| | Skin Tests | 3 | 2012 | 116 | 0.110 |
Why?
| | Aged | 13 | 2019 | 18969 | 0.110 |
Why?
| | Comorbidity | 5 | 2018 | 1447 | 0.110 |
Why?
| | Lipids | 1 | 2017 | 564 | 0.110 |
Why?
| | Recombinant Proteins | 6 | 2006 | 1228 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2020 | 1836 | 0.110 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.110 |
Why?
| | Network Meta-Analysis | 2 | 2023 | 12 | 0.110 |
Why?
| | Young Adult | 10 | 2019 | 10444 | 0.110 |
Why?
| | Health Status | 1 | 2018 | 716 | 0.110 |
Why?
| | Logistic Models | 4 | 2019 | 1829 | 0.100 |
Why?
| | Cholecalciferol | 1 | 2013 | 47 | 0.100 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 714 | 0.100 |
Why?
| | RNA, Messenger | 9 | 2007 | 2550 | 0.100 |
Why?
| | Research Design | 1 | 2018 | 919 | 0.100 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 4 | 0.100 |
Why?
| | Vitamins | 1 | 2013 | 150 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2013 | 247 | 0.100 |
Why?
| | Vitamin D | 2 | 2013 | 340 | 0.100 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 265 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2011 | 1880 | 0.100 |
Why?
| | Signal Transduction | 2 | 2023 | 4501 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2011 | 1947 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2010 | 959 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 489 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 2 | 2008 | 11 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 526 | 0.090 |
Why?
| | Th1-Th2 Balance | 1 | 2010 | 9 | 0.090 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 145 | 0.090 |
Why?
| | Histamine Antagonists | 1 | 2010 | 20 | 0.090 |
Why?
| | Receptors, Chemokine | 1 | 2010 | 44 | 0.090 |
Why?
| | Hypertension | 1 | 2018 | 1052 | 0.090 |
Why?
| | Cardiovascular Diseases | 2 | 2018 | 1726 | 0.090 |
Why?
| | Chickenpox Vaccine | 1 | 2010 | 69 | 0.090 |
Why?
| | Therapies, Investigational | 1 | 2010 | 14 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 25 | 0.090 |
Why?
| | Mice | 9 | 2012 | 14843 | 0.090 |
Why?
| | Genetic Variation | 2 | 2011 | 868 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 2885 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2013 | 459 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2010 | 138 | 0.080 |
Why?
| | Pediatrics | 2 | 2015 | 982 | 0.080 |
Why?
| | Disease Outbreaks | 1 | 2012 | 305 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2019 | 6306 | 0.080 |
Why?
| | Adjuvants, Immunologic | 3 | 2004 | 206 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2015 | 949 | 0.080 |
Why?
| | Coal Tar | 1 | 2008 | 2 | 0.080 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 742 | 0.080 |
Why?
| | Environmental Exposure | 1 | 2012 | 372 | 0.080 |
Why?
| | Cell Degranulation | 1 | 2008 | 39 | 0.080 |
Why?
| | Phenotype | 4 | 2023 | 2784 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 686 | 0.080 |
Why?
| | Pyroglyphidae | 2 | 2022 | 17 | 0.080 |
Why?
| | Irritants | 1 | 2008 | 41 | 0.080 |
Why?
| | Quality Improvement | 1 | 2016 | 944 | 0.080 |
Why?
| | Basophils | 1 | 2008 | 64 | 0.080 |
Why?
| | Dosage Forms | 1 | 2008 | 10 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1815 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 610 | 0.080 |
Why?
| | United Kingdom | 2 | 2019 | 226 | 0.080 |
Why?
| | S100 Proteins | 1 | 2008 | 37 | 0.070 |
Why?
| | Mast Cells | 1 | 2008 | 116 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2014 | 1117 | 0.070 |
Why?
| | Reference Values | 2 | 2019 | 739 | 0.070 |
Why?
| | Cathelicidins | 4 | 2010 | 38 | 0.070 |
Why?
| | Clinical Protocols | 1 | 2008 | 232 | 0.070 |
Why?
| | Protein Precursors | 1 | 2007 | 119 | 0.070 |
Why?
| | Drug Combinations | 3 | 2020 | 286 | 0.070 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2006 | 12 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2010 | 377 | 0.070 |
Why?
| | Immunohistochemistry | 6 | 2010 | 1624 | 0.070 |
Why?
| | Virus Replication | 2 | 2006 | 395 | 0.070 |
Why?
| | Cost-Benefit Analysis | 3 | 2018 | 544 | 0.070 |
Why?
| | Patient Dropouts | 1 | 2007 | 66 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.070 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1036 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 68 | 0.070 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 2006 | 15 | 0.070 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2006 | 53 | 0.070 |
Why?
| | Proteins | 2 | 2010 | 906 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1128 | 0.060 |
Why?
| | Gene Frequency | 3 | 2013 | 476 | 0.060 |
Why?
| | Immunoglobulins | 2 | 2005 | 143 | 0.060 |
Why?
| | Thiazoles | 1 | 2006 | 110 | 0.060 |
Why?
| | Thyroid Diseases | 1 | 2005 | 31 | 0.060 |
Why?
| | Models, Immunological | 1 | 2005 | 90 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2023 | 766 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2004 | 44 | 0.060 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 189 | 0.060 |
Why?
| | Resorcinols | 1 | 2023 | 4 | 0.060 |
Why?
| | Interleukins | 1 | 2006 | 236 | 0.060 |
Why?
| | Patient Care Team | 1 | 2008 | 517 | 0.060 |
Why?
| | Stilbenes | 1 | 2023 | 36 | 0.060 |
Why?
| | Lactams | 2 | 1995 | 18 | 0.060 |
Why?
| | Acute Disease | 6 | 2008 | 907 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2019 | 384 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 429 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 293 | 0.050 |
Why?
| | Janus Kinase 1 | 1 | 2023 | 23 | 0.050 |
Why?
| | Leukocyte Count | 2 | 1995 | 292 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 13 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2003 | 8 | 0.050 |
Why?
| | Risk | 2 | 2018 | 810 | 0.050 |
Why?
| | Patient Compliance | 1 | 2007 | 524 | 0.050 |
Why?
| | Prednisone | 2 | 1994 | 229 | 0.050 |
Why?
| | Caregivers | 2 | 2023 | 713 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 3315 | 0.050 |
Why?
| | Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
| | Prospective Studies | 2 | 2020 | 6195 | 0.050 |
Why?
| | Conflict of Interest | 1 | 2004 | 119 | 0.050 |
Why?
| | Fibronectins | 1 | 2023 | 108 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2003 | 104 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2023 | 109 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 3 | 2013 | 489 | 0.050 |
Why?
| | Lymphoma | 2 | 2018 | 176 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 59 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 473 | 0.050 |
Why?
| | Granuloma, Respiratory Tract | 1 | 2002 | 12 | 0.050 |
Why?
| | Insurance, Physician Services | 1 | 2002 | 3 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.050 |
Why?
| | Baths | 1 | 2022 | 17 | 0.050 |
Why?
| | Langerhans Cells | 1 | 2001 | 11 | 0.050 |
Why?
| | Eosinophils | 2 | 1995 | 276 | 0.050 |
Why?
| | 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 11 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3498 | 0.050 |
Why?
| | Time Factors | 2 | 2007 | 6077 | 0.050 |
Why?
| | North America | 1 | 2022 | 255 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 91 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2002 | 74 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2384 | 0.050 |
Why?
| | Diet | 2 | 2022 | 1080 | 0.050 |
Why?
| | Gene Expression | 3 | 2007 | 1417 | 0.050 |
Why?
| | Claudin-1 | 2 | 2011 | 21 | 0.050 |
Why?
| | Beryllium | 1 | 2002 | 146 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2022 | 327 | 0.050 |
Why?
| | Placebos | 1 | 2021 | 197 | 0.040 |
Why?
| | Health Expenditures | 1 | 2002 | 172 | 0.040 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 787 | 0.040 |
Why?
| | Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
| | Markov Chains | 2 | 2015 | 114 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 2958 | 0.040 |
Why?
| | Chemokines, CXC | 2 | 2003 | 60 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2002 | 580 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 380 | 0.040 |
Why?
| | Leg Dermatoses | 1 | 2019 | 1 | 0.040 |
Why?
| | Scalp Dermatoses | 1 | 2019 | 2 | 0.040 |
Why?
| | Foot Dermatoses | 1 | 2019 | 4 | 0.040 |
Why?
| | Buttocks | 1 | 2019 | 10 | 0.040 |
Why?
| | Facial Dermatoses | 1 | 2019 | 14 | 0.040 |
Why?
| | Hand Dermatoses | 1 | 2019 | 7 | 0.040 |
Why?
| | Biopsy | 4 | 2007 | 1024 | 0.040 |
Why?
| | Genitalia | 1 | 2019 | 28 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2011 | 339 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 132 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 2011 | 22 | 0.040 |
Why?
| | Haplotypes | 2 | 2011 | 448 | 0.040 |
Why?
| | Torso | 1 | 2019 | 28 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 145 | 0.040 |
Why?
| | Interleukin-16 | 1 | 1998 | 6 | 0.040 |
Why?
| | Autoantigens | 1 | 2001 | 396 | 0.040 |
Why?
| | Acetamides | 1 | 2018 | 25 | 0.040 |
Why?
| | Canada | 1 | 2020 | 320 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.040 |
Why?
| | Skin Diseases, Bacterial | 1 | 2018 | 22 | 0.040 |
Why?
| | Association | 1 | 2018 | 11 | 0.040 |
Why?
| | Phthalic Acids | 1 | 2018 | 28 | 0.040 |
Why?
| | Arm | 1 | 2019 | 104 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2018 | 32 | 0.040 |
Why?
| | Pilot Projects | 2 | 1995 | 1360 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 111 | 0.040 |
Why?
| | Medicaid | 1 | 2002 | 404 | 0.040 |
Why?
| | Age Distribution | 1 | 2018 | 341 | 0.040 |
Why?
| | Herpesvirus 2, Human | 2 | 2009 | 27 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 336 | 0.040 |
Why?
| | Fundoplication | 1 | 1997 | 51 | 0.040 |
Why?
| | Immune System | 1 | 2018 | 171 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 815 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 172 | 0.040 |
Why?
| | Quinazolines | 1 | 2018 | 240 | 0.030 |
Why?
| | Peak Expiratory Flow Rate | 2 | 1993 | 33 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2019 | 481 | 0.030 |
Why?
| | Monocytes | 2 | 2002 | 503 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 408 | 0.030 |
Why?
| | Texas | 2 | 2008 | 188 | 0.030 |
Why?
| | Forced Expiratory Volume | 2 | 1997 | 471 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 608 | 0.030 |
Why?
| | Health Occupations | 1 | 1996 | 28 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 735 | 0.030 |
Why?
| | Rhinitis, Allergic | 1 | 2016 | 35 | 0.030 |
Why?
| | Interleukin-12 | 1 | 1996 | 110 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 631 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1996 | 294 | 0.030 |
Why?
| | Penicillins | 1 | 1995 | 52 | 0.030 |
Why?
| | Whey Proteins | 1 | 2015 | 5 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 419 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 924 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1422 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 1997 | 229 | 0.030 |
Why?
| | Cohort Studies | 2 | 2015 | 4883 | 0.030 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 363 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1996 | 120 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1080 | 0.030 |
Why?
| | Legionellosis | 1 | 1994 | 2 | 0.030 |
Why?
| | Legionnaires' Disease | 1 | 1994 | 4 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2010 | 990 | 0.030 |
Why?
| | Dermatitis, Irritant | 2 | 2004 | 11 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 77 | 0.030 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 24 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 1995 | 77 | 0.030 |
Why?
| | Milk | 1 | 2015 | 123 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 441 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 317 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 140 | 0.030 |
Why?
| | Methylprednisolone | 1 | 1994 | 80 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3003 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1996 | 313 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1706 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 1993 | 29 | 0.030 |
Why?
| | Laparoscopy | 1 | 1997 | 395 | 0.030 |
Why?
| | Chemokine CXCL10 | 2 | 2009 | 34 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2019 | 479 | 0.030 |
Why?
| | Anaphylaxis | 1 | 1996 | 144 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2006 | 1144 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 183 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1757 | 0.030 |
Why?
| | Respiratory System | 1 | 1993 | 137 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2011 | 2562 | 0.030 |
Why?
| | Chemokines | 2 | 2006 | 215 | 0.030 |
Why?
| | Cockroaches | 1 | 2012 | 21 | 0.030 |
Why?
| | Treatment Failure | 1 | 1993 | 330 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2764 | 0.030 |
Why?
| | Haptens | 1 | 1992 | 21 | 0.020 |
Why?
| | Patient Care | 1 | 2013 | 99 | 0.020 |
Why?
| | Cats | 1 | 2012 | 193 | 0.020 |
Why?
| | Vaccinia | 1 | 2011 | 18 | 0.020 |
Why?
| | Microbiota | 1 | 2019 | 648 | 0.020 |
Why?
| | Family | 1 | 2015 | 589 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 513 | 0.020 |
Why?
| | Lung Diseases | 1 | 1997 | 690 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 331 | 0.020 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1991 | 25 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 47 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1791 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 396 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1762 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2010 | 176 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3338 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2314 | 0.020 |
Why?
| | Lung | 1 | 2002 | 3521 | 0.020 |
Why?
| | Chemokine CCL27 | 1 | 2009 | 1 | 0.020 |
Why?
| | Chemokine CCL17 | 1 | 2009 | 4 | 0.020 |
Why?
| | Health Care Costs | 2 | 2003 | 381 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 444 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 373 | 0.020 |
Why?
| | Interferon-beta | 1 | 2009 | 79 | 0.020 |
Why?
| | Skin Physiological Phenomena | 1 | 2008 | 26 | 0.020 |
Why?
| | Herpesvirus 1, Human | 1 | 2009 | 76 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 107 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 14 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 569 | 0.020 |
Why?
| | Fluticasone | 1 | 2007 | 87 | 0.020 |
Why?
| | Chemokine CCL20 | 1 | 2006 | 4 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 1998 | 292 | 0.020 |
Why?
| | Androstadienes | 1 | 2007 | 97 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2505 | 0.020 |
Why?
| | Thiazolidines | 1 | 2006 | 7 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2006 | 26 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 84 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2009 | 520 | 0.020 |
Why?
| | Vitis | 1 | 2006 | 38 | 0.020 |
Why?
| | Apoptosis | 1 | 1995 | 2349 | 0.020 |
Why?
| | Europe | 1 | 2006 | 332 | 0.020 |
Why?
| | Genomics | 1 | 2010 | 631 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2008 | 1218 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2005 | 63 | 0.020 |
Why?
| | Erythema | 1 | 2004 | 25 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 5038 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2005 | 149 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2006 | 222 | 0.010 |
Why?
| | Case Management | 1 | 2004 | 61 | 0.010 |
Why?
| | Rats | 1 | 2012 | 4913 | 0.010 |
Why?
| | DNA, Viral | 1 | 2006 | 349 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2006 | 475 | 0.010 |
Why?
| | Collagen Type III | 1 | 2003 | 15 | 0.010 |
Why?
| | Retreatment | 1 | 2003 | 67 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2006 | 435 | 0.010 |
Why?
| | Societies, Medical | 1 | 2006 | 655 | 0.010 |
Why?
| | Collagen Type I | 1 | 2003 | 108 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2629 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 18 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1089 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 725 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2003 | 274 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 153 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2114 | 0.010 |
Why?
| | Cooperative Behavior | 1 | 2004 | 376 | 0.010 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2003 | 88 | 0.010 |
Why?
| | Health Services | 1 | 2003 | 103 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 180 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1696 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2004 | 571 | 0.010 |
Why?
| | Chemotactic Factors, Eosinophil | 1 | 2000 | 6 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 802 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 309 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 445 | 0.010 |
Why?
| | Chemokine CCL11 | 1 | 2000 | 22 | 0.010 |
Why?
| | Odds Ratio | 1 | 2003 | 951 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 237 | 0.010 |
Why?
| | Receptors, Interleukin-5 | 1 | 1998 | 5 | 0.010 |
Why?
| | Receptors, Interleukin-12 | 1 | 1998 | 6 | 0.010 |
Why?
| | Receptors, Interleukin-4 | 1 | 1998 | 15 | 0.010 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 12 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2002 | 1075 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 12521 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 1981 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 863 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2783 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1611 | 0.010 |
Why?
| | Colorado | 1 | 2006 | 4090 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1997 | 522 | 0.010 |
Why?
| | Immunocompetence | 1 | 1994 | 40 | 0.010 |
Why?
| | Interleukin-5 | 1 | 1994 | 30 | 0.010 |
Why?
| | Methacholine Chloride | 1 | 1993 | 47 | 0.010 |
Why?
| | Bronchial Provocation Tests | 1 | 1993 | 47 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1994 | 281 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 150 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1993 | 229 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1993 | 163 | 0.010 |
Why?
| | Bronchi | 1 | 1993 | 223 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1993 | 637 | 0.010 |
Why?
| | Neoplasms | 1 | 2005 | 2086 | 0.010 |
Why?
| | Cell Survival | 1 | 1995 | 1014 | 0.010 |
Why?
| | Enterotoxins | 1 | 1991 | 88 | 0.010 |
Why?
| | Macrophages, Alveolar | 1 | 1993 | 348 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1991 | 119 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1991 | 122 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1993 | 965 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1993 | 1310 | 0.000 |
Why?
|
|
Boguniewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|